2025 American Academy of Neurology Abstract Website

Objective:

To determine whether the use of Dabigratran can reduce the length of hospitalization due to Cerebral Venous Thrombosis (CVT).

Background:

From the current available evidence, it is reasonable to transition to Direct Oral Anticoagulants or Warfarin after a period of lead-in parenteral anticoagulation in the treatment CVT. But whether 5 to 15 days to do the transition to oral anticoagulants is a safer or more effective strategy than shorter periods is not known.

Design/Methods:

A retrospective, single-center, longitudinal study evaluating data from the electronic medical records of patients of both sexes hospitalized for CVT from 2014 to 2019 (Warfarin) and from 2019 to 2023 (Dabigatran). Statistical analyses were carried out using SPSS 21 (Statistical Package for the Social Sciences) software.

Results:

A total of 131 patients were included: 70 in the Warfarin Group (WG) and 61 in the Dabigatran Group (DG). In the WG, there were 54 women (77,1%), and in the DG there were 38 women (62,3%), the mean age (SD) of the patients was 37,0 (±10,7), and 38,6 (±11,7), respectively. Within 3 months of follow up none of the groups had a recurrence and all had recanalization. The mean (SD) length of hospital stay in the WG was 5.5 days (±2,1), and in the DG, it was 3,7 days (±1,1). The statistical test T of Student demonstrated that there are statistically significant differences (T(135)= 5.55; p<0.05) between the average length of hospital stay, with the average of the WG group being greater compared to the DG group, a difference between them of 1.71 days.

Conclusions:

Transition from heparin to oral anticoagulants within 5 days was safe and effective in this coorte. Dabigatran can reduce the length of hospital stay even further, as it does not require dose adjustments according to the international standard of 2 to 3, which is necessary with Warfarin.